Domestic Healthcare Cost-Containment Measures and Healthcare System Reform
First written in FY2016. 23 of 26 entries say "Restated". Latest entry: 2026-07-30.
1 other company's latest entry also says "Restated".
- 2026-07-30RestatedEarnings
「In the clinical testing reagent industry, the operating environment is becoming increasingly challenging due to the continued rise in logistics and raw material procurement costs resulting from the weaker yen and higher crude oil prices.」
The company continues to describe the challenging industry environment resulting from measures to restrain medical costs. - FY2026ReframedAnnual report
「If healthcare cost-containment measures or pharmaceutical regulations are strengthened as a result of developments in healthcare system reform in various countries, if the operation of colorectal cancer screening programs changes, or if environmental regulations on diagnostic reagents and medical devices are strengthened, product prices, product usage, regulatory applications, bidding conditions, and other matters may be affected, which could affect the group's financial position and operating results.」
The company reorganized the scope of its regulatory risks by adding changes in screening-program operations and environmental regulations on diagnostic reagents and medical devices to the existing risks related to healthcare cost containment and healthcare system reform. - FY2026-H1RestatedAnnual report
「In the clinical diagnostics industry, the operating environment has become even more challenging due to the continued increase in logistics and raw-material procurement costs resulting from healthcare cost-containment measures. Companies are required to further strengthen their cost competitiveness and expand strategically into overseas markets.」
The company continues to describe the challenging industry environment caused by healthcare cost-containment measures and the need for cost competitiveness and overseas expansion. - FY2024-Q1RestatedAnnual report
「In the clinical diagnostics industry, the operating environment has become even more challenging due to healthcare cost-containment measures and higher costs for resources, logistics, and raw-material procurement, requiring companies to further strengthen their cost competitiveness and actively expand overseas.」
The company continues to describe the challenging domestic industry environment caused by healthcare cost-containment measures and the need for cost competitiveness and active overseas expansion. - FY2023-Q3RestatedAnnual report
「In the clinical diagnostics industry, the operating environment has become even more challenging due to healthcare cost-containment measures and higher costs for resources, logistics, and raw-material procurement during the COVID-19 pandemic, requiring companies to further strengthen their cost competitiveness and actively expand overseas.」
The company continues to describe the challenging domestic industry environment caused by healthcare cost-containment measures and the need for cost competitiveness and active overseas expansion. - FY2023-Q2RestatedAnnual report
「In the clinical diagnostics industry, the operating environment has become even more challenging due to healthcare cost-containment measures and higher costs for resources, logistics, and raw-material procurement during the COVID-19 pandemic, requiring companies to further strengthen their cost competitiveness and actively expand overseas.」
The company continues to describe the challenging domestic industry environment caused by healthcare cost-containment measures and the need for cost competitiveness and active overseas expansion. - FY2023-Q1RestatedAnnual report
「In the clinical diagnostics industry, the operating environment has become even more challenging due to healthcare cost-containment measures and higher logistics and raw-material procurement costs during the COVID-19 pandemic, requiring companies to further strengthen their cost competitiveness and actively expand overseas.」
The company continues to describe the challenging industry environment caused by healthcare cost-containment measures and the need for cost competitiveness and active overseas expansion. - FY2022RestatedAnnual report
「In the clinical diagnostics industry, the operating environment has become even more challenging due to healthcare cost-containment measures and higher logistics and raw-material procurement costs during the COVID-19 pandemic, requiring companies to further strengthen their cost competitiveness and actively expand overseas.」
The company continues to face a challenging domestic industry environment due to healthcare cost-containment measures and the need for cost competitiveness and overseas expansion. - FY2022-Q3RestatedAnnual report
「In the clinical diagnostics industry, the operating environment has become even more challenging due to healthcare cost-containment measures and higher logistics and raw-material procurement costs during the COVID-19 pandemic, requiring companies to further strengthen their cost competitiveness and actively expand overseas.」
The company continues to describe the challenging industry environment caused by healthcare cost-containment measures and the need for cost competitiveness and overseas expansion. Higher logistics and raw-material costs have been classified separately as a new risk. - FY2022-Q2RestatedAnnual report
「In the clinical diagnostics industry, a challenging operating environment continues due to healthcare cost-containment measures, requiring companies to further strengthen their cost competitiveness and actively expand overseas.」
The company continues to describe the challenging domestic industry environment caused by healthcare cost-containment measures and the need for cost competitiveness and active overseas expansion. - FY2021-Q2RestatedAnnual report
「In addition to these external factors, the clinical diagnostics industry continues to face a challenging operating environment due to healthcare cost-containment measures, requiring companies to further strengthen their cost competitiveness and actively expand overseas.」
The company continues to describe the challenging domestic industry environment caused by healthcare cost-containment measures and the need for cost competitiveness and active overseas expansion. - FY2020RestatedAnnual report
「In Japan, community-based integrated care systems are expected to be promoted against a backdrop including the diversification of healthcare and long-term care needs in an aging society, while healthcare system reform to contain healthcare costs continues.」
The company continues to identify healthcare cost containment and healthcare system reform as risks in the domestic business environment. - FY2020-Q2RestatedAnnual report
「In the clinical diagnostics industry, a challenging operating environment continues due to healthcare cost-containment measures, requiring companies to further strengthen their cost competitiveness and actively expand overseas.」
The company continues to describe the challenging domestic industry environment caused by healthcare cost-containment measures and the need for cost competitiveness and overseas expansion. - FY2020-Q1RestatedAnnual report
「In the clinical diagnostics industry, a challenging operating environment continues due to healthcare cost-containment measures, requiring companies to further strengthen their cost competitiveness and actively expand overseas.」
The company continues to describe the challenging domestic industry environment caused by healthcare cost-containment measures and the need for cost competitiveness and overseas expansion. - FY2019-Q3RestatedAnnual report
「In the clinical diagnostics industry, a challenging operating environment continues due to healthcare cost-containment measures, requiring companies to further strengthen their cost competitiveness and actively expand overseas. Overseas, continued growth is expected from demand for greater efficiency to contain healthcare costs in developed countries, the expansion of preventive medicine, and the development of healthcare infrastructure accompanying population growth and economic development in emerging countries.」
The company continues to describe the challenging domestic industry environment caused by healthcare cost-containment measures and the need for cost competitiveness and overseas expansion. - FY2019-Q2RestatedAnnual report
「In the clinical diagnostics industry, a challenging operating environment continues due to healthcare cost-containment measures, requiring companies to further strengthen their cost competitiveness and actively expand overseas. Overseas, continued growth is expected from demand for greater efficiency to contain healthcare costs in developed countries, the expansion of preventive medicine, and the development of healthcare infrastructure accompanying population growth and economic development in emerging countries.」
The company continues to describe the challenging domestic industry environment caused by healthcare cost-containment measures and the need for cost competitiveness and overseas expansion. It states that there have been no new risks or significant changes. - FY2019-Q1RestatedAnnual report
「In the clinical diagnostics industry, a challenging operating environment continues due to healthcare cost-containment measures, requiring companies to further strengthen their cost competitiveness and actively expand overseas.」
The company continues to describe the challenging domestic industry environment caused by healthcare cost-containment measures and the need for cost competitiveness and overseas expansion. No quantification of the risks or new developments is indicated. - FY2018RestatedAnnual report
「Japan has implemented healthcare system reforms in response to the declining birth rate, population aging, and other factors, and healthcare cost containment continues. The clinical diagnostics market is also subject to the Pharmaceuticals and Medical Devices Act and related regulations. If the company is slow to respond to sales competition associated with healthcare cost containment or changes in related laws and regulations, its financial position and operating results may be affected.」
The company continues to identify delayed responses to related laws and regulations and sales competition, in addition to healthcare cost containment and healthcare system reform, as risks to the domestic market. - FY2018-Q3RestatedAnnual report
「In the clinical diagnostics industry, a challenging operating environment continues due to healthcare cost-containment measures, requiring companies to further strengthen their cost competitiveness and actively expand overseas.」
The company continues to describe the challenging domestic industry environment caused by healthcare cost-containment measures and the need for cost competitiveness and overseas expansion. - FY2018-Q2RestatedAnnual report
「In the clinical diagnostics industry, a challenging operating environment continues due to healthcare cost-containment measures, requiring companies to further strengthen their cost competitiveness and actively expand overseas.」
The company continues to describe the challenging domestic industry environment caused by healthcare cost-containment measures and the need for cost competitiveness and overseas expansion. - FY2018-Q1RestatedAnnual report
「In the clinical diagnostics industry, a challenging operating environment continues due to healthcare cost-containment measures, requiring companies to further strengthen their cost competitiveness and actively expand overseas.」
The company continues to describe the challenging domestic industry environment caused by healthcare cost-containment measures and the need for cost competitiveness and overseas expansion. - FY2017RestatedAnnual report
「Japan has continued to implement healthcare system reforms to contain healthcare costs. If these cost-containment measures continue to be advanced, they may affect the group's financial position and operating results.」
The company continues to identify healthcare system reform and healthcare cost-containment measures as risks to the domestic market. - FY2017-Q3RestatedAnnual report
「In the clinical diagnostics industry, the FY2016 revision of medical fee schedules was implemented amid ongoing healthcare system reform, and fees for specimen testing declined only modestly, by approximately 0.4% overall.」
The company continues to disclose the decline in specimen-testing fees resulting from healthcare system reform and revisions to medical fees. - FY2017-Q2RestatedAnnual report
「In the clinical diagnostics industry, the FY2016 revision of medical fee schedules was implemented amid ongoing healthcare system reform, and fees for specimen testing declined only modestly, by approximately 0.4% overall.」
The company continues to disclose the revision of medical fees and the decline in specimen-testing fees. It also states that there have been no significant changes in business and other risks. - FY2017-Q1MaterialisedAnnual report
「In the clinical diagnostics industry, the FY2016 revision of medical fee schedules was implemented amid ongoing healthcare system reform, and fees for specimen testing declined only modestly, by approximately 0.4% overall.」
In connection with healthcare system reform and healthcare cost-containment measures, medical fee revisions and a decline in specimen-testing fees have occurred. - FY2016First statedAnnual report
「Japan has continued to implement healthcare system reforms to contain healthcare costs. If these cost-containment measures continue to be advanced, they may affect the group's financial position and operating results.」
This is identified as an external-environment risk for the domestic clinical diagnostics market.